Artificial heart technology company Scandinavian Real Heart AB (Nasdaq Stockholm First North Growth Market:HEART) announced on Wednesday that it has received patent approval from the European Patent Office for its Realheart TAH (Total Artificial Heart) technology.

The unitary patent, valid in 17 European Union countries including Sweden, France, and Germany, protects the device's core structure, function, and integrated feedback mechanism through 2041 (Patent No. 4120893).

Realheart TAH is designed to mimic the structure and function of the human heart and provide accurate, real-time pressure measurements. The patented sensor enables automated regulation of cardiac output, supporting artificial heart and circulatory systems.

The technology aims to offer a meaningful treatment alternative for patients awaiting heart transplants. Its structural design also seeks to reduce risks commonly associated with current artificial heart devices, such as stroke, internal bleeding, and anaemia.